诊断学理论与实践 ›› 2016, Vol. 15 ›› Issue (06): 567-572.doi: 10.16150/j.1671-2870.2016.06.005
杨丽艳, 王化泉
收稿日期:2016-10-19
出版日期:2016-12-25
发布日期:2022-07-27
通讯作者:
王化泉 E-mail: wanghuaquan@tmu.edu.cn
基金资助:
Received:2016-10-19
Online:2016-12-25
Published:2022-07-27
中图分类号:
杨丽艳, 王化泉. 血小板生成素受体激动剂的作用机制及其在骨髓增生异常综合征治疗中的应用[J]. 诊断学理论与实践, 2016, 15(06): 567-572.
| [1] Greenberg PL, Attar E, Bennett JM, et al.Myelodysplastic syndromes: clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2013,11(7):838-874. [2] Pang WW, Pluvinage JV, Price EA, et al.Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes[J]. Proc Natl Acad Sci U S A,2013,110(8):3011-3016. [3] Ma X, Does M, Raza A, et al.Myelodysplastic syndromes: incidence and survival in the United States[J]. Cancer,2007,109(8):1536-1542. [4] Kantarjian H, Giles F, List A, et al.The incidence and impact of thrombocytopenia in myelodysplastic syndromes[J]. Cancer,2007,109(9):1705-1714. [5] Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J]. Cancer,2008,113(6):1351-1361. [6] Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes[J]. Am J Hematol,2008,83(10):765-770. [7] Sekeres MA, Schoonen WM, Kantarjian H, et al.Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys[J]. J Natl Cancer Inst,2008,100(21):1542-1551. [8] Goodnough LT, DiPersio JF. Issues in the management of cancer-related thrombocytopenia[J]. Oncology (Williston Park),2002,16(11):1558-1567,1570,1572-1574. [9] Yamada M, Komatsu N, Kirito K, et al.Thrombopoietin supports [10] Kuter DJ.New thrombopoietic growth factors[J]. Clin Lymphoma Myeloma,2009,9(Suppl 3):S347-S356. [11] Kuter DJ.Romiplostim[J]. Cancer Treat Res,2011,157:267-288. [12] Broudy VC, Lin NL.AMG531 stimulates megakaryopoiesis [13] Erickson-Miller C, Tian S, Hopson C, et al.Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115[J]. Transfusion,2005,45S(3):43A. [14] Erickson-Miller CL, Delorme E, Tian SS, et al.Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist[J]. Stem Cells,2009, 27(2):424-430. [15] Haselboeck J, Pabinger I, Ay C, et al.Platelet activation and function during eltrombopag treatment in immune thrombocytopenia[J]. Ann Hematol,2012,91(1):109-113. [16] Bussel JB, Kuter DJ, Pullarkat V, et al.Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP[J]. Blood,2009,113(10):2161-2171. [17] Kantarjian H, Fenaux P, Sekeres MA, et al.Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia[J]. J Clin Oncol,2010,28(3):437-444. [18] Sekeres MA, Kantarjian H, Fenaux P, et al.Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes[J]. Cancer,2011,117(5):992-1000. [19] Giagounidis A, Mufti GJ, Fenaux P, et al.Results of a randomized, double-blind study of romiplostim [20] Santini V.Novel therapeutic strategies: hypomethylating agents and beyond[J]. Hematology Am Soc Hematol Educ Program,2012,2012:65-73. [21] Santini V, Fenaux P, Mufti GJ, et al.Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*[J]. Eur J Haematol,2010,85(2):130-138. [22] Kantarjian HM, Giles FJ, Greenberg PL, et al.Phase 2 study of romiplostim in patients with low- or interme-diate-risk myelodysplastic syndrome receiving azacitidine therapy[J]. Blood,2010,116(17):3163-3170. [23] Greenberg PL, Garcia-Manero G, Moore M, et al.A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine[J]. Leuk Lymphoma,2013,54(2):321-328. [24] Jädersten M, Hellström-Lindberg E.Myelodysplastic syndromes: biology and treatment[J]. J Intern Med,2009,265(3):307-328. [25] Mohamedali A, Mufti GJ.Van-den Berghe's 5q- syndrome in 2008[J]. Br J Haematol,2009,144(2):157-168. [26] List A, Dewald G, Bennett J, et al.Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med,2006,355(14):1456-1465. [27] Wang ES, Lyons RM, Larson RA, et al.A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide[J]. J Hematol Oncol,2012, 5:71. [28] Prica A, Sholzberg M, Buckstein R.Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials[J]. Br J Haematol,2014,167(5):626-638. [29] Mavroudi I, Pyrovolaki K, Pavlaki K, et al.Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome[J]. Leuk Res,2011,35(3):323-328. [30] Tamari R, Schinke C, Bhagat T, et al.Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone[J]. Leuk Lymphoma,2014,55(12):2901-2906. [31] Sellers T, Hart T, Semanik M, et al.Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs[J]. Blood,2004,104(111):568A. [32] Jenkins JM, Williams D, Deng Y, et al.Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist[J]. Blood,2007,109(11):4739-4741. [33] Will B, Kawahara M, Luciano JP, et al.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood,2009, 114(18):3899-3908. [34] Svensson T, Chowdhury O, Garelius H, et al.A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine[J]. Eur J Haematol,2014,93(5):439-445. [35] Dickinson M, Herbert K, Sardjono C, et al.High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML[J]. Leuk Res,2013,371:S147. [36] Oliva EN, Santini V, Zini G, et al.Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial[J]. Leuk Res,2013,371:S162. [37] Oliva EN, Santini V, Zini G, et al.Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial(EQoL-MDS)[J]. Blood,2012,120(21). [38] Kalina U, Hofmann WK, Koschmieder S, et al.Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes[J]. Exp Hematol,2000,28(10):1158-1163. [39] Luo SS, Ogata K, Yokose N, et al.Effect of thrombo-poietin on proliferation of blasts from patients with myelodysplastic syndromes[J]. Stem Cells,2000,18(2):112-119. [40] Platzbecker U, Wong RS, Verma A, et al.Safety and tole-rability of eltrombopag [41] Will B, Kawahara M, Luciano J P, et al.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood,2009, 114(18):3899-3908. [42] Kalota A, Gewirtz AM.A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells[J]. Blood,2010,115(1):89-93. [43] Roth M, Will B, Simkin G, et al.Eltrombopag inhibits the proliferation of leukemia cells [44] Erickson-Miller CL, Kirchner J, Aivado M, et al.Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag[J]. Leuk Res,2010,34(9):1224-1231. [45] Mavroudi I, Pyrovolaki K, Pavlaki K, et al.Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome[J]. Leuk Res,2011,35(3):323-328. [46] Sugita M, Kalota A, Gewirtz AM, et al.Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression[J]. Leukemia,2013,27(5):1207-1210. |
| [1] | 刘萍, 肖园, 王歆琼, 陆亭伟, 赵雪松, 杨媛艳. Wiskott-Aldrich综合征合并克罗恩病一例并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 349-354. |
| [2] | 王柔嘉, 常春康. 调节性T细胞在骨髓增生异常综合征危险分层中的研究进展[J]. 诊断学理论与实践, 2021, 20(02): 221-224. |
| [3] | 叶成林, 姚永华, 陈真, 贾麟. 骨髓活检塑胶包埋在以单纯血小板减少为表现的骨髓增生异常综合征诊断中的应用价值[J]. 诊断学理论与实践, 2020, 19(02): 177-181. |
| [4] | 吴凌云, 常春康. 骨髓增生异常综合征的诊治最新进展[J]. 诊断学理论与实践, 2019, 18(06): 623-629. |
| [5] | 杜云志, 冯菁华, 常春康. 二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 685-671. |
| [6] | 宋丹丹, 常春康, 郭娟, 许峰, 赵佑山, 吴凌云. 骨髓增生异常综合征患者骨髓巨噬细胞百分比异常及其意义[J]. 诊断学理论与实践, 2018, 17(04): 439-443. |
| [7] | 李坦, 李斌, 刘媛媛, 鲍扬漪. 原发免疫性血小板减少症患者外周血Treg细胞程序性死亡受体-1的表达[J]. 诊断学理论与实践, 2018, 17(03): 294-298. |
| [8] | 王敏敏, 曾惠, 郭晓珺. CD4+CD25+CD127-/low调节性T细胞和Th17细胞在ITP发病中的研究进展[J]. 诊断学理论与实践, 2018, 17(02): 220-224. |
| [9] | 师蕾, 常春康. 间充质干细胞在骨髓增生异常综合征发病机制中的研究进展[J]. 诊断学理论与实践, 2018, 17(01): 123-126. |
| [10] | 蔡晓红, 雷航, 王学锋. 2017年英国血液学标准委员会《血小板输注指南》和要点解读[J]. 诊断学理论与实践, 2017, 16(03): 264-269. |
| [11] | 肖志坚. 骨髓增生异常综合征的诊断[J]. 诊断学理论与实践, 2016, 15(06): 545-549. |
| [12] | 赵智刚, 王金焕. 骨髓微环境调控骨髓增生异常综合征的作用及相关机制[J]. 诊断学理论与实践, 2016, 15(06): 550-555. |
| [13] | 宋陆茜, 常春康. 二代测序技术在骨髓增生异常综合征诊治中的临床应用[J]. 诊断学理论与实践, 2016, 15(06): 556-560. |
| [14] | 肖超, 常春康. 骨髓增生异常综合征的铁过载诊断和铁螯合治疗[J]. 诊断学理论与实践, 2016, 15(06): 561-566. |
| [15] | 任艳玲, 佟红艳. 骨髓增生异常综合征常用药物治疗的机制[J]. 诊断学理论与实践, 2016, 15(06): 573-577. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
